Ver Investigador - - Prisma - Unidad de Bibliometría

Francisco Manuel Vega Moreno

Tipo Año Título Fuente
Artículo2023 Analysis of serial neuroblastoma PDX passages in mice allows the identification of new mediators of neuroblastoma aggressiveness INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2022 A protocol to enrich in undifferentiated cells from neuroblastoma tumor tissue samples and cell lines STAR Protocols
Editorial2021 Non-canonical kinases and substrates in cancer progression CANCERS
Letter2020 A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity CELL DISCOVERY
Corrección2020 Corrigendum to ‘CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours’ (EBioMedicine (2019) 49 (82–95), (S235239641930711X), (10.1016/j.ebiom.2019.10.041)) EBIOMEDICINE
Revisión2020 Hypoxia in the initiation and progression of neuroblastoma tumours INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2020 Identification of VRK1 as a new neuroblastoma tumor progression marker regulating cell proliferation CANCERS
Nota2020 Response to “High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma” EBIOMEDICINE
Artículo2019 CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours EBIOMEDICINE
Revisión2018 The RhoB small GTPase in physiology and disease Small GTPases
Artículo2017 Association of high microvessel alpha(v)beta(3) and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126 ONCOTARGET
Artículo2017 Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma ONCOTARGET
Artículo2017 The atheroma plaque secretome stimulates the mobilization of endothelial progenitor cells ex vivo JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Artículo2016 Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation Scientific reports
Artículo2015 The Rho GTPase RhoB regulates cadherin expression and epithelial cell-cell interaction CELL COMMUNICATION AND SIGNALING
Artículo2013 Estudio de expresión de marcadores de células madre neurales en neuroblastoma y correlación con factores pronóstico Cirugía Pediátrica
Artículo2012 Cdc42 promotes transendothelial migration of cancer cells through beta 1 integrin JOURNAL OF CELL BIOLOGY
Artículo2012 RhoB regulates cell migration through altered focal adhesion dynamics OPEN BIOLOGY
Artículo2011 RhoA and RhoC have distinct roles in migration and invasion by acting through different targets JOURNAL OF CELL BIOLOGY
Revisión2011 Roles of VRK1 as a new player in the control of biological processes required for cell division CELLULAR SIGNALLING
Artículo2008 Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer PROTEOMICS CLINICAL APPLICATIONS
Revisión2008 Rho GTPases in cancer cell biology FEBS LETTERS
Artículo2008 The C/H3 Domain of p300 Is Required to Protect VRK1 and VRK2 from their Downregulation Induced by p53 PLOS ONE
Artículo2007 Identification of a human epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Revisión2007 Snapshot: Rho family GTPases CELL
Artículo2006 p53 downregulates its activating vaccinia-related kinase 1 (VRK1) forming a new autoregulatory loop MOLECULAR AND CELLULAR BIOLOGY
Artículo2006 Rac1 and Rac2 regulate macrophage morphology but are not essential for migration JOURNAL OF CELL SCIENCE
Artículo2006 Subcellular localization of vaccinia-related kinase 2 (VRK2) isoforms determines their different effects on p53 stability in tumour cell lines FEBS JOURNAL
Artículo2006 VRK1 Signaling pathway in the context of the proliferation phenotype in Head and Neck squamous cell carcinoma MOLECULAR CANCER RESEARCH
Artículo2004 c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK) ONCOGENE
Artículo2004 Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK JOURNAL OF BIOLOGICAL CHEMISTRY
Artículo2004 p53 Stabilization and accumulation induced by human vaccinia-related kinase 1 MOLECULAR AND CELLULAR BIOLOGY
Artículo2004 The vaccinia virus B1R kinase induces p53 downregulation by and Mdm2-dependent mechanism Virology
Artículo2003 Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development FEBS LETTERS
Artículo2002 Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1 ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Artículo1999 Trimeric G proteins modulate the dynamic interaction of PKAII with the Golgi complex JOURNAL OF CELL SCIENCE

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
01/09/2023 31/08/2026 Responsable Revelando señalización específica en células indiferenciadas de la cresta neural: nuevas oportunidades de tratamiento para el neuroblastoma agresivo (PID2022-142424OB-I00) Ministerio de Ciencia e Innovación (Nacional)
01/06/2020 31/12/2023 Responsable Heterogeneidad Celular Derivada de la Cresta Neural Simpatoadrenal: Implicaciones en la Progresión y el Tratamiento de los Neuroblastomas (PID2019-110817RB-I00) Ministerio de Ciencia, Innovación y Universidades (Nacional)
01/02/2020 30/04/2022 Responsable Fisiopatología Celular y Molecular de los Neuroblastomas Agresivos (US-1262985) Junta de Andalucía (Consejería de Economía y Conocimiento) (Autonómico)
01/01/2020 31/12/2022 Responsable Fisiopatología Celular y Molecular de los Neuroblastomas Agresivos (P18-RT-3151) Junta de Andalucía (Consejería de Economía y Conocimiento) (Autonómico)
01/01/2014 31/12/2017 Investigador/a Fisiopatología de Células Madre Derivadas de la Cresta Neural (SAF2013-48535-P) Ministerio de Economía y Competitividad (Nacional)

Contratos

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
11/01/2022 30/06/2023 Investigador/a High-throughput screening for novel rejuvenation factors (4368/1142) YouthBio Therapeutics Inc. (Desconocido)
El investigador no tiene ningún resultado de investigación asociado